Metformin after bone cancer treatment to prevent relapse
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have osteosarcoma or Ewing sarcoma, and the cancer is not metastatic (not spread to other body parts)
- Be at least 14 years old
- Be in a high-risk situation: after initial chemotherapy with low tumor necrosis or after being disease-free following a first relapse (per the study’s timing rules)
- Have the right timing: able to start screening and begin metformin within about 30–45 days after finishing chemotherapy or local surgery/relapse
- Be able to swallow pills and not be in another clinical study
- Have good kidney and liver function on screening labs (and you should not have certain kidney/liver or oxygen-blood-flow problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
This trial tests adding metformin, a common diabetes drug, to the usual first cancer treatment for advanced soft tissue sarcoma. It may help the standard therapy work better.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.